Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT05534399
Starting soon Not applicable

Antibiotic Strategy and Asymptomatic Bacteriuria in the Context of Intra-vesical Botulinum Toxin A Injections.

NCT05534399 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Lille
Phase
Not applicable
Started
2026-05
Last updated
2025-12-26

Condition(s) studied

Urinary Tract Disease

Investigational drug(s) / intervention(s)

Intra-vesical BoNTA injections

Intra-vesical BoNTA injections: Intra-vesical BoNTA injections will be performed according to the protocol currently applied by the department. They will be performed in the operating room or in the outpatient clinic under strict asepsis, including the wearing of sterile gloves by the surgeon associated with an antiseptic brushing of the patient and the establishment of sterile fields. A rigid or a flexible cystoscope will be used. After the introduction of the cystoscope under visual control, complete bladder emptying will be performed. The bladder will be filled again, slowly and at low pressure to allow the bladder mucosa to expand. BoNTA (BOTOX® 200 U) will be diluted as follows: BOTOX® 200 U: in 30 mL of saline solution The solution obtained will be injected all along the bladder wall, sparing the trigone in 20 (BOTOX® 200 U) points using a Bonee®-type needle. A complete bladder emptying will be performed at the end of the procedure.

Study summary

The study aims to demonstrate that the "thrifty antibiotic strategy" applied to MS or SCI patients with asymptomatic bacteriuria prior to BoNTA intravesical injections does not increase the rate of symptomatic post-injection UTIs compared to the current peri-operative antibiotic strategy.

Patients included in the study will be randomized in two balanced-parallel groups, 4 days (+/- 2 days) before intra-vesical BoNTA injections.

Group 1: Experimental group: "Sparing antibiotic strategy" No antibiotic therapy will be administered during the peri-operative period.

Group 2: Control group: Recommendations - Peri-operative antibiotic strategy An antibiotic therapy will be administered during the peri-operative period. The antibiotic will be selected according to the type of bacteria isolated and the antibiotic susceptibility testing, and started two days before and pursued until two days following intra-vesical BoNTA injections.

The main objective is to demonstrate the non-inferiority of "antibiotic saving strategy" compared to peri-operative antibiotic strategy (current recommendations) for occurrence of symptomatic UTI after intra-vesical BoNTA injections in the management of asymptomatic bacteriuria (AB) among multiple sclerosis (MS) and spinal cord injured (SCI) patients undergoing clean intermittent self-catheterization (CISC).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * MS or SCI (traumatic or non-traumatic) * Refractory OAB and/or DO (failure, intolerance or contra-indication to anti-muscarinic therapy) * Treated with intra-vesical botulinum toxin A injections having proved efficacy * CISC as the exclusive bladder management * AB on pre-operative urine analysis (performed 10 days (+/- 2 days) before intra-vesical BoNTA injections) * Exclusion of morphologic urinary tract abnormalities considered as a risk factor for recurrent symptomatic UTI. Exclusion Criteria: * Having already participated to the study * Augmentation cystoplasty * Bladder compliance disorders (\<20 mL/cmH2O) * Ongoing cyclic antibiotic therapy * Ongoing corticosteroid therapy * Modification of immunosuppressive or immunomodulatory therapy in the 3 months before inclusion (MS patients) * Antibiotic therapy in the month before inclusion * Surgical procedure in the 3 months before and the 6 weeks following inclusion * Symptomatic UTI at the time of inclusion * Associated neurologic disease * Pregnancy or breast feeding * Individuals especially in need of protection * No informed consent * Patients incapable to follow the trial, e.g. because of language problems, psychiatric disorders, dementia and so on * Immunocompromised patients

Primary outcome measure(s)

  • Rate of patients with symptomatic UTI occurring within the 6 weeks following the injections. — During the 6 weeks following the injections
    Symptomatic UTI will be defined according to the National Institute on Disability and Rehabilitation Research (NIDRR, 1992) as a significant bacteriuria with tissue invasion and resultant tissue response with signs and/or symptoms of UTI

Trial sites (1)

FacilityCityRegionStatus
Hop Claude Huriez Chu Lille Lille France

More University Hospital, Lille trials in France

Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO Recruiting
Effectiveness of Erector Spinae Plane Block for Percutaneous Arthrodesis of Spinal Fractures Active, not recruiting
Performance of Carbon Dioxide (CO2)-Derived Parameters in Predicting Low Cardiac Output Syndrome Recruiting
Bone Marrow Fat and Bariatric Surgery-Mediated Bone Loss Recruiting
Intact Cord Resuscitation in CDH Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05534399 on ClinicalTrials.gov ↗ ← All trials in France